TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
Last tg therapeutics, inc earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
| Impact snapshot | Event time: | TGTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
TGTX alerts
TGTX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet HaematologyGlobeNewswire
- Is This Cheap Cancer-Drug Company a Top Stock to Buy Now? [The Motley Fool]The Motley Fool
- TG Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TGTX/price-target/">NASDAQ: TGTX</a>) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.MarketBeat
- TG Therapeutics, Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/TGTX/price-target/">NASDAQ: TGTX</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FLBusiness Wire
- More
TGTX
SEC Filings
- 2/16/21 - Form SC
- 2/12/21 - Form 5
- 2/10/21 - Form SC
- TGTX's page on the SEC website
- More